C91.42
Hairy cell leukemia, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Hairy cell leukemia (HCL) is a rare type of chronic leukemia that primarily affects B-lymphocytes, a kind of white blood cell involved in the immune response. When HCL recurs after initial treatment, it is referred to as a relapse. The classification code C91.42 is used by healthcare professionals for this specific condition. During a relapse, the disease progresses again after a period of remission, necessitating renewed medical attention and management to control symptoms and prevent complications.
Causes & Symptoms
Clinical Causes: The exact cause of hairy cell leukemia remains unknown, but genetic mutations are believed to play a role. Previous treatment resistance can sometimes lead to relapse. Environmental factors and exposure to certain chemicals or radiation may contribute, although evidence is limited. In some cases, the disease may recur without identifiable triggers.
Key Symptoms: Persistent fatigue and weakness Frequent infections due to weakened immune system Swelling or pain in the lymph nodes, spleen, or liver Unintended weight loss Easy bruising or bleeding Fever or night sweats Painless swelling of the spleen and sometimes the liver Anemia symptoms such as pallor and shortness of breath
Diagnostic & Treatment
Diagnosis Path: Diagnosing a relapse of hairy cell leukemia involves a combination of blood tests, bone marrow examination, and imaging studies. Key steps include: - **Blood counts**: Reduced levels of red blood cells, white blood cells, and platelets indicate ongoing marrow suppression. - **Peripheral blood smear**: Identifies characteristic hairy cells. - **Bone marrow biopsy**: Confirms disease presence and assesses the extent. - **Immunophenotyping**: Uses flow cytometry to detect specific markers on hairy cells. - **Imaging studies**: Ultrasound or CT scans of the spleen and other organs to evaluate involvement.
Treatment Protocols: Managing hairy cell leukemia in relapse may involve several therapeutic options aimed at controlling symptoms and prolonging remission: - **Chemotherapy**: Purine analogs like cladribine and pentostatin are commonly used to target hairy cells. - **Immunotherapy**: Monoclonal antibodies such as rituximab can help destroy malignant cells. - **Splenectomy**: Surgical removal of the spleen might be considered in certain cases to reduce disease burden. - **Targeted therapy**: Emerging treatments focusing on specific genetic mutations are under investigation. - **Supportive care**: Includes blood transfusions, antibiotics for infections, and growth factors to support blood cell production. Close monitoring and personalized treatment strategies are essential, given the potential for disease recurrence.
Clinical Advice & FAQs
Billing Guidance
Is C91.42 a billable ICD-10 code?
Yes, C91.42 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.42?
Clinical documentation must specify the nature of Hairy cell leukemia, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference